499 related articles for article (PubMed ID: 8876234)
21. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells.
Heidenreich O; Krauter J; Riehle H; Hadwiger P; John M; Heil G; Vornlocher HP; Nordheim A
Blood; 2003 Apr; 101(8):3157-63. PubMed ID: 12480707
[TBL] [Abstract][Full Text] [Related]
22. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
[TBL] [Abstract][Full Text] [Related]
23. The AML1 and ETO genes in acute myeloid leukemia with a t(8;21).
Nucifora G; Rowley JD
Leuk Lymphoma; 1994 Aug; 14(5-6):353-62. PubMed ID: 7812194
[TBL] [Abstract][Full Text] [Related]
24. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
Zent CS; Mathieu C; Claxton DF; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1044-8. PubMed ID: 8577711
[TBL] [Abstract][Full Text] [Related]
25. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.
Yuan Y; Zhou L; Miyamoto T; Iwasaki H; Harakawa N; Hetherington CJ; Burel SA; Lagasse E; Weissman IL; Akashi K; Zhang DE
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10398-403. PubMed ID: 11526243
[TBL] [Abstract][Full Text] [Related]
26. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
[TBL] [Abstract][Full Text] [Related]
28. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation.
Westendorf JJ; Yamamoto CM; Lenny N; Downing JR; Selsted ME; Hiebert SW
Mol Cell Biol; 1998 Jan; 18(1):322-33. PubMed ID: 9418879
[TBL] [Abstract][Full Text] [Related]
29. Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells.
Era T; Asou N; Kunisada T; Yamasaki H; Asou H; Kamada N; Nishikawa S; Yamaguchi K; Takatsuki K
Genes Chromosomes Cancer; 1995 May; 13(1):25-33. PubMed ID: 7541640
[TBL] [Abstract][Full Text] [Related]
30. The ETO domain is necessary for the developmental abnormalities associated with AML1-ETO expression in the hematopoietic stem cell compartment in vivo.
de Guzman CG; Johnson A; Klug CA
Blood Cells Mol Dis; 2003; 30(2):201-6. PubMed ID: 12732184
[TBL] [Abstract][Full Text] [Related]
31. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
[TBL] [Abstract][Full Text] [Related]
33. Expression of AML1 and ETO Transcripts in hematopoietic cells.
Era T; Asou N; Yamaguchi K; Yamasaki H; Kamada N; Nishikawa S; Takatsuki K
Leukemia; 1995 Oct; 9 Suppl 1():S26-8. PubMed ID: 7475308
[TBL] [Abstract][Full Text] [Related]
34. Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia.
Miyamoto T; Nagafuji K; Harada M; Niho Y
Leuk Lymphoma; 1997 Mar; 25(1-2):69-75. PubMed ID: 9130615
[TBL] [Abstract][Full Text] [Related]
35. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.
Jurlander J; Caligiuri MA; Ruutu T; Baer MR; Strout MP; Oberkircher AR; Hoffmann L; Ball ED; Frei-Lahr DA; Christiansen NP; Block AM; Knuutila S; Herzig GP; Bloomfield CD
Blood; 1996 Sep; 88(6):2183-91. PubMed ID: 8822938
[TBL] [Abstract][Full Text] [Related]
36. Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continous clinical remission.
Guerrasio A; Rosso C; Martinelli G; Lo Coco F; Pampinella M; Santoro A; Lanza C; Allione B; Resegotti L; Saglio G
Br J Haematol; 1995 Jun; 90(2):364-8. PubMed ID: 7794758
[TBL] [Abstract][Full Text] [Related]
37. Transformation properties of the ETO gene, fusion partner in t(8:21) leukemias.
Wang J; Wang M; Liu JM
Cancer Res; 1997 Jul; 57(14):2951-5. PubMed ID: 9230207
[TBL] [Abstract][Full Text] [Related]
38. Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia.
Zhang Y; Strissel P; Strick R; Chen J; Nucifora G; Le Beau MM; Larson RA; Rowley JD
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3070-5. PubMed ID: 11867721
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETO.
Berg T; Fliegauf M; Burger J; Staege MS; Liu S; Martinez N; Heidenreich O; Burdach S; Haferlach T; Werner MH; Lübbert M
Haematologica; 2008 Nov; 93(11):1728-33. PubMed ID: 18790797
[TBL] [Abstract][Full Text] [Related]
40. Specific protein redirection as a transcriptional therapy approach for t(8;21) leukemia.
Steffen B; Serve H; Berdel WE; Agrawal S; Linggi B; Büchner T; Hiebert SW; Müller-Tidow C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8448-53. PubMed ID: 12819347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
